Fezolinetant for Treating Hot Flashes in Men With Prostate Cancer

This study is for men with prostate cancer who are experiencing hot flashes due to treatments that lower testosterone. Hot flashes can affect your quality of life and make it harder for patients to continue their treatment, so researchers want to find a better way to manage them. The study is testing a drug called fezolinetant, which might help reduce hot flashes without using hormones. Fezolinetant is a drug that is currently approved for the treatment of hot flashes in menopausal women.

Trial Details

NCT ID
NCT06972875
Phase
PHASE2
Sponsor
University of Vermont
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • Fezolinetant
Locations (sample)
  • Burlington, Vermont, United States|44.47588,-73.21207

Key Eligibility Criteria

  • Age ≥ 18 years Men who are currently receiving Androgen Deprivation Therapy (ADT) for the treatment of prostate cancer. ADT is defined by a history…
  • Patients must be on a stable dose of all hormonal therapies for at least 28 days prior to registration and must not be planning to discontinue this…
  • Patients receiving radiation therapy during the study period are eligible. An eligible patient must have bothersome hot flashes for ≥ 7 days prior …
  • Life Expectancy of 6 months or greater. Language: In order to complete the mandatory participant-completed measures, participants must be able to s…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →